Skip to main content
. 2016 Jul 26;11(15):1947–1955. doi: 10.2217/nnm-2016-0147

Figure 2. . All docetaxel therapies decrease tumor burden, but PRINT-C2-docetaxel improves survival.

Figure 2. 

(A) The tumor volume changes among treatment groups are similar to each other, but all are significantly better than the PBS control (p < 0.0001). (B) PRINT-C2-docetaxel improved median survival by greater than 35% over all other treatments and PBS.